People in the News

Waters has appointed Richard Fearon to its board of directors. Fearon is the former vice chairman and chief financial and planning officer of multinational power management company Eaton. Prior to joining Eaton in 2002, he served in senior corporate and strategic planning roles at companies including Transamerica, NatSteel, and Walt Disney. He holds an AB in economics from Stanford University, an MBA from Harvard Business School, and a JD from Harvard Law School.

AdvaMedDx has named Qiagen CEO Thierry Bernard as chairperson of the board of directors, succeeding Bio-Rad Laboratories CEO Norman Schwartz. AdvaMed represents more than 75 manufacturers of in vitro diagnostic tests and technologies in the US and abroad. Bernard joined Qiagen in 2015 and has served as CEO since 2019. He previously held executive positions at BioMérieux.

New Zealand cancer diagnostics company Pacific Edge has appointed Glen Costin to the new role of president, Asia Pacific, to lead the buildout of the company's APAC business. Previous to joining Pacific Edge, Costin led his own firm, MDL Asia, assisting with the APAC expansion of small and medium-sized medical, diagnostics, and life science companies. Prior to that, he held senior positions at Abcam, Bio-Rad Laboratories, and Becton Dickinson. Pacific Edge's lead product is the urine-based Cxbladder test, which measures gene expression to detect or rule out the presence of bladder cancer.

Linda De Jesus has been appointed as VP and general manager, global head of commercial, of Integrated DNA Technologies. Most recently, she was senior VP and chief commercial officer at Azenta Life Sciences, and before that, she was VP and general manager for the chromatography and mass spectrometry division of Thermo Fisher Scientific. De Jesus holds an executive MBA from the University of Connecticut School of Business and a bachelor's degree in chemistry from Columbia University.

Mark Stevenson has joined global growth equity firm General Atlantic as a senior advisor. Until his retirement last year, he was executive VP and chief operating officer of Thermo Fisher Scientific, where he is still a member of the scientific advisory board. He joined Thermo Fisher in 2014 as president of the Life Sciences Solutions unit after the firm acquired Life Technologies, where he was president and chief operating officer. Before that, he held the same titles at Applied Biosystems, which merged with Invitrogen in 2008 to form Life Technologies. Stevenson holds an MBA from Henley Management School and a bachelor's degree in chemistry from the University of Reading in the UK.

Akoya Biosciences has appointed Johnny Ek as its new CFO, taking over for Joe Driscoll, who retired from his position on Monday. Ek joined Akoya from Specific Diagnostics (acquired by BioMérieux last year), where he served as CFO. Prior to that, he served as CFO at GenMark Diagnostics.

Claire Fraser has stepped down as director of the Institute for Genome Sciences at the University of Maryland School of Medicine, but will remain a professor of medicine as well as microbiology and immunology and a researcher at IGS until her retirement next year. Jacques Ravel, professor of microbiology and immunology at UMSOM, has become acting director of IGS. Fraser founded IGS in 2007 after leaving The Institute for Genomic Research (TIGR), where she was president. TIGR in 2006 became a division of the J. Craig Venter Institute, founded by Fraser's former husband Craig Venter. She holds a PhD in pharmacology from the State University of New York Buffalo.

Standard BioTools has appointed Fenel Eloi to its board of directors. Eloi, who will also serve on the board's audit committee, was most recently CFO and chief operating officer of Cell Signaling Technology. Previously, he was COO and CFO at Interleukin Genetics. Eloi has also served as CFO at LifeCell and Genome Therapeutics.

Concurrent with Eloi's appointment, Bill Colston will retire from the company's board.

Gencove has appointed Alex Dickinson to its board of directors. Dickinson is cofounder and a director for ChromaCode, a molecular diagnostics firm. He was senior VP at Illumina where he helped build BaseSpace and led that firm's global population sequencing program. He was also cofounder and CEO of Helixis and Luxtera. Dickinson holds a doctorate in electrical engineering from the University of Adelaide and an MBA from Columbia University.

Biocept has terminated the employment of Michael Dugan, its CMO and medical director, effective March 17, the firm said in a document filed with the US Securities and Exchange Commission. Biocept gave no reason for the action but said it has promoted Associate Medical Director Nathaniel Sweed to medical director and designated an undisclosed new medical director of the company's CLIA-certified, CAP-accredited clinical lab in San Diego. Dugan joined Biocept in August 2020.